ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors.

Dirk Timmerman ,Tom Bourne ,Guillermo J Gallardo ,David Cibula ,Andreas Du Bois ,Birthe Lemley ,Annika Loft ,Nicole Concin ,Ignace Vergote ,Giovanni Scambia ,D Fischerová ,Wouter Froyman ,Philippe Morice ,Vincent Vandecaveye ,Luis Chiva ,François Planchamp ,C Landolfo ,Denis Querleu ,Liliana Mereu ,Antonia Carla Testa ,Christina Fotopoulou

doi:10.1002/uog.23635

Abstract

The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the preoperative diagnosis of ovarian tumors, including imaging techniques, biomarkers and prediction models. ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the preoperative diagnosis of ovarian tumors and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements. This Consensus Statement presents these ESGO/ISUOG/IOTA/ESGE statements on the preoperative diagnosis of ovarian tumors and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.

Highlights

The accurate characterization of newly diagnosed adnexal lesions is of paramount importance to define appropriate treatment pathways
Patients with masses that are suspicious for malignancy should be referred to a gynecological oncology center, in order to receive specialist care, as per the definitions of the European Society of Gynaecological Oncology (ESGO)[1] and national and international recommendations and guidelines
General remarks Even though the test performance of any biochemical or radiological diagnostic test appears to increase after excluding borderline ovarian tumors and non-g ynecological primary tumors, such as of the gastrointestinal tract or breast, we included in our literature assessment studies addressing all types of adnexal tumor, as this is a better reflection of clinical reality